July 26th 2024
A user-friendly “nudge” may provide a timely reminder to surgeons to consider the value of sentinel lymph node biopsy in older patients with breast cancer.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Bevacizumab/Chemo Before WBRT May Better Control Breast Cancer Brain Metastases
January 9th 2024Data from the phase 2 A-PLUS trial indicate that bevacizumab plus chemotherapy prior to whole brain radiotherapy may be an efficacious systemic strategy for intractable brain and extracranial metastases stemming from breast cancer.
Importance of Managing Nausea Related to T-DXd in HR+ Breast Cancer
January 7th 2024Sarah Donahue, MPH, NP, discusses her strategy for administering doxorubicin, cyclophosphamide, and antiemetics to manage nausea following trastuzumab deruxtecan therapy for patients with hormone receptor–positive breast cancer.
QOL vs Survival Should be Considered Prior to Chemo in Geriatric TNBC
January 4th 2024Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Toxicity After Chemo May be Avoided With Anastrozole Combo in Breast Cancer
December 25th 2023It may be possible to use anastrozole plus palbociclib, trastuzumab, and pertuzumab in place of chemotherapy in the frontline setting for hormone receptor–positive, HER2-positive metastatic breast cancer, says Amy Tiersten, MD.
Anastrozole Combo Yields High Clinical Benefit in HR+/HER2+ Breast Cancer
December 23rd 2023A future phase 2 trial may compare anastrozole plus a CDK4/6 inhibitor and trastuzumab or pertuzumab with chemotherapy plus trastuzumab and pertuzumab in hormone receptor–positive, HER2-positive metastatic breast cancer.
Communication Is ‘Key’ for Successful Oncoplastic Surgery in Breast Cancer
December 23rd 2023Oncoplastic surgery requires collaboration between different surgical teams, pathologists, and radiologists to ensure optimal cosmetic and survival outcomes for patients with breast cancer, says Roshani Patel, MD, FACS.
Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC
December 21st 2023Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.
Liquid Biopsy May Predict T-DXd Activity in HER2+ Metastatic Breast
December 13th 2023It is important to look at different assays beyond immunohistochemistry to better gather information and potentially predict the activity of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer, says Paolo Tarantino, MD.
Ribociclib Combo Yields iDFS Improvement in HR+/HER2– Breast Cancer
December 9th 2023Combining ribociclib with nonsteroidal aromatase inhibitor treatment also produces relapse-free survival and distant disease-free survival benefits in patients with HR-positive, HER2-negative early-stage breast cancer.